Format

Send to

Choose Destination
World J Gastroenterol. 2018 Oct 7;24(37):4254-4262. doi: 10.3748/wjg.v24.i37.4254.

VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice.

Author information

1
Department of Gastroenterology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
2
National Cancer Center/Cancer Hospital, CAMS and PUMC, Beijing 100021, China.
3
Department of Gastroenterology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. lijn2008@126.com.

Abstract

AIM:

To investigate the effects of VSL#3 on tumor formation, and fecal and intestinal mucosal microbiota in azoxymethane/dextran sulfate sodium (AOM/DSS) induced mice model.

METHODS:

C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis (UC) carcinogenesis model. Mice were treated with 5-ASA (75 mg/kg/d), VSL#3 (1.5 × 109 CFU/d), or 5-ASA combined with VSL#3 by gavage from the day of AOM injection for three months (five days/week). The tumor load was compared in each group, and tumor necrosis factor (TNF-α) and interleukin (IL)-6 levels were evaluated in colon tissue. The stool and intestinal mucosa samples were collected to analyze the differences in the intestinal microbiota by 16s rDNA sequencing method.

RESULTS:

VSL#3 significantly reduced the tumor load in AOM/DSS-induced mice model and decreased the level of TNF-α and IL-6 in colon tissue. The model group had a lower level of Lactobacillus and higher level of Oscillibacter and Lachnoclostridium in fecal microbiota than the control group. After the intervention with 5-ASA and VSL#3, Bacillus and Lactococcus were increased, while Lachnoclostridium and Oscillibacter were reduced. 5-ASA combined with VSL#3 increased the Lactobacillus and decreased the Oscillibacter. The intestinal mucosal microbiota analysis showed a lower level of Bifidobacterium and Ruminococcaceae_UCG-014 and higher level of Alloprevotella in the model group as compared to the control group. After supplementation with VSL#3, Bifidobacterium was increased. 5-ASA combined with VSL#3 increased the level of both Lachnoclostridium and Bifidobacterium.

CONCLUSION:

VSL#3 can prevent UC-associated carcinogenesis in mice, reduce the colonic mucosal inflammation levels, and rebalance the fecal and mucosal intestinal microbiota.

KEYWORDS:

Interleukin-6; Intestinal microbiota; Tumor necrosis factor-α; Ulcerative colitis carcinogenesis; VSL#3

PMID:
30310258
PMCID:
PMC6175759
DOI:
10.3748/wjg.v24.i37.4254
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center